Notably, CAR-T cell therapy has achieved significant clinical success against B-cell malignancies, and the first CAR-T cell therapy was approved in 2017 for CD19-directed CAR-T cell therapy against r/r B-ALL and diffuse large B cell lymphoma (DLBCL). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.